Search Results - "Stöhlmacher, Jan"

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial by Vermorken, Jan B, Dr, Stöhlmacher-Williams, Jan, MD, Davidenko, Irina, MD, Licitra, Lisa, MD, Winquist, Eric, MD, Villanueva, Cristian, MD, Foa, Paolo, MD, Rottey, Sylvie, MD, Skladowski, Krzysztof, MD, Tahara, Makoto, MD, Pai, Vasant R, MD, Faivre, Sandrine, MD, Blajman, Cesar R, MD, Forastiere, Arlene A, MD, Stein, Brian N, MBBS, Oliner, Kelly S, PhD, Pan, Zhiying, PhD, Bach, Bruce A, MD

“…Summary Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve clinical outcomes of patients with recurrent or metastatic…”
Get full text

Pharmacogenetics in gastrointestinal tumors by Stöhlmacher, Jan

“…Treatment of gastrointestinal cancers has significantly advanced over the last few years with the introduction of effective chemotherapeutic and targeted…”
Get more information

TFAP2E–DKK4 and Chemoresistance in Colorectal Cancer by Ebert, Matthias P.A, Tänzer, Marc, Balluff, Benjamin, Burgermeister, Elke, Kretzschmar, Antje Karen, Hughes, David J, Tetzner, Reimo, Lofton-Day, Catherine, Rosenberg, Robert, Reinacher-Schick, Anke C, Schulmann, Karsten, Tannapfel, Andrea, Hofheinz, Ralf, Röcken, Christoph, Keller, Gisela, Langer, Rupert, Specht, Katja, Porschen, Rainer, Stöhlmacher-Williams, Jan, Schuster, Tibor, Ströbel, Philipp, Schmid, Roland M

“…Patients whose tumors showed methylation and decreased expression of the gene TFAP2E were more than five times as likely as patients with normal TFAP2E gene…”
Get full text

Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer by Grimminger, Peter P, Stöhlmacher, Jan, Vallböhmer, Daniel, Schneider, Paul M, Hölscher, Arnulf H, Metzger, Ralf, Danenberg, Peter V, Brabender, Jan

“…Background. To further improve the screening, diagnosis, and therapy of patients with nonsmall cell lung cancer (NSCLC) additional diagnostic tools are…”
Get full text

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer by Sebastian, Martin, Schröder, Andreas, Scheel, Birgit, Hong, Henoch S., Muth, Anke, von Boehmer, Lotta, Zippelius, Alfred, Mayer, Frank, Reck, Martin, Atanackovic, Djordje, Thomas, Michael, Schneller, Folker, Stöhlmacher, Jan, Bernhard, Helga, Gröschel, Andreas, Lander, Thomas, Probst, Jochen, Strack, Tanja, Wiegand, Volker, Gnad-Vogt, Ulrike, Kallen, Karl-Josef, Hoerr, Ingmar, von der Muelbe, Florian, Fotin-Mleczek, Mariola, Knuth, Alexander, Koch, Sven D.

“…CV9201 is an RNActive ® -based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma…”
Get full text

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer by Stein, Alexander, Atanackovic, Djordje, Hildebrandt, Bert, Stübs, Patrick, Brugger, Wolfram, Hapke, Gunnar, Steffens, Claus-Christoph, Illerhaus, Gerald, Bluemner, Ernst, Stöhlmacher, Jan, Bokemeyer, Carsten

“…Background: The addition of bevacizumab (BEV) to standard doublet chemotherapy improves outcomes compared with chemotherapy alone in patients with metastatic…”
Get full text

A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer by Schmid-Bindert, Gerald, Engel-Riedel, Walburga, Reck, Martin, Schuette, Wolfgang, Stöhlmacher, Jan, Fischer, Jürgen R, Mazières, Julien, Chouaid, Christos, Wolf, Martin, Vinolas, Nuria, Soldatenkova, Victoria, Ripoche, Veronique, Nguyen, Tuan, Visseren-Grul, Carla

“…Highlights • Feasibility of adjuvant cisplatin or carboplatin + pemetrexed in Stage IB/II NSCLC. • Feasibility definition based on safety, tolerability, and…”
Get full text

Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease by Hoffknecht, Petra, Tufman, Amanda, Wehler, Thomas, Pelzer, Theo, Wiewrodt, Rainer, Schütz, Martin, Serke, Monika, Stöhlmacher-Williams, Jan, Märten, Angela, Maria Huber, Rudolf, Dickgreber, Nicolas J

“…Afatinib is an effective first-line treatment in patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) and has shown…”
Get more information

First-line therapy of mutated non-small cell lung cancer: an update by Stöhlmacher-Williams, Jan

“…Currently, many treatment options and new targets for cancer therapies for patients with advanced non-small cell lung cancer (NSCLC) are being evaluated. This…”
Get more information

EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma by Hoffmann, Andreas-Claudius, Goekkurt, Eray, Danenberg, Peter V, Lehmann, Sylvia, Ehninger, Gerhard, Aust, Daniela E, Stoehlmacher-Williams, Jan

“…Cholangiocarcinoma remains to be a tumor with very few treatment choices and limited prognosis. In this study, we sought to determine the prognostic role of…”
Get full text